Altered day regarding financial information for Active Biotech

Altered day regarding financial information for Active Biotech Interim report, nine months, will be published on Monday, 22 November 1999, and not, as previously indicated, on 25 November. Final accounts report for 1999 will be published on 18 February 2000. Lund 12 November 1999 Active Biotech AB (publ) Sven Andréasson President & CEO Active Biotech AB is a Swedish biotechnology group focused on the research and development of pharmaceuticals and vaccines. Our core competence is knowledge of the human immune defence system. We have a high qualitative project portfolio and considerable financial resources. Important products are the Cholera-vaccine, vaccine against tourist diarrhoea (ETEC), and innovative drugs against MS (SAIK). The turnover of Active Biotech was SEK259 million in 1998. Active Biotech AB Box 724, S-220 07 Lund, Sweden Tel +46 46-19 20 00 Fax +46 46 19 20 50 E-mail info@activebiotech.com ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/11/12/19991112BIT00250/bit0001.pdf http://www.bit.se/bitonline/1999/11/12/19991112BIT00250/bit0002.doc

About Us

Active Biotech's activity is in the biomedical area. The company focuses on R & D.